Further development combining MEK and MET inhibition [86] is being further evaluated in clinical studies (NCT02510001) to target both downstream signaling and putative adaptive resistance for the treatment of KRAS-mutant CRC. Here, MAP2K7 is linked to colorectal carcinoma.